EPI-506 is currently being tested in patients with advanced prostate cancer (clinicaltrials.gov)
Prostate Cancer has the highest incidence and is the second most common cause of death in men1. Generally, prostate cancer growth is dependent on the interaction of androgens with the androgen receptor.
Initially, prostate cancer is sensitive to medical or surgical therapies that decrease androgen levels (i.e., androgen deprivation therapy). However, once disease progression occurs, this generally represents a transition to the lethal form of prostate cancer, called castration-resistant prostate cancer (CRPC).
12016, American Cancer Society, Inc., Surveillance Research
Revolutionizing the Way Prostate Cancer is Treated
Many CRPC patients will have been treated with Xtandi® (enzalutamide) or Zytiga® (abiraterone) or both, the current standard-of-care drugs in metastatic CRPC.
However, resistance to these therapies can occur over time and effective treatments in this setting are needed.
ESSA’s novel approach to blocking the androgen receptor with the EPI compounds has been shown to be effective in preclinical studies by inhibiting prostate cancer cell proliferation and tumor growth (see Publications).
The EPI-506 Trial
ESSA is currently conducting a Phase 1/2 clinical trial of EPI-506 in patients with metastatic CRPC.
During Phase 1 (dose escalation), the study is evaluating the safety, tolerability, pharmacokinetics, and maximum tolerated dose of once-daily dosing with EPI-506. During Phase 2 (dose expansion), the study will evaluate the efficacy of EPI-506 in patients with CRPC who have failed abiraterone or enzalutamide or both.
EPI-506 is the first androgen receptor N-terminal domain inhibitor to be tested in clinical trials.
The study is currently enrolling in the United States and Canada (Clinicaltrials.gov# NCT02606123; study number EPI-506- CS-0001).